CompletedNot Applicable

A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy

China272 participantsStarted 2020-01-01

Plain-language summary

Surgery is still the main treatment for esophageal cancer, however, the complication and mortality rate of open esophagectomy is high. As a result, the thoracoscopic- laparoscopic minimally invasive esophagectomy (MIE) was developed. The MIE mainly comprised two surgical approaches: MIE McKeown approach (cervical anastomosis) and MIE Ivor-Lewis approach (intrathoracicanastomosis). The MIE with intrathoracic anastomosis (Ivor-Lewis) is increasingly used for the treatment of mid and lower esophageal cancers. Our study is trying to compare the safety, feasibility, and short-term and long- term outcomes between MIE Ivor-Lewis approach and MIE McKeown approach for the treatment of lower thoracic esophageal cancer and esophageal- gastric junction.

Who can participate

Age range30 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: (I) Patients with clinically staged T1-3N0-2M0 tumors; good cardiopulmonary function; (II) Patients with lower thoracic esophageal tumors and esophageal- gastric junction tumor; (III) Patients without a previous history of cancer; (IV) Patients without a previous history of neck or chest surgery; Exclusion Criteria: (I) cardiopulmonary function not good enough for surgery; (II) Patients with hybrid MIE

What they're measuring

Overall postoperative complications

Timeframe: within one month

Trial details

NCT IDNCT04217239

SponsorThe Second Hospital of Shandong University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Esophageal Cancer trials